-
公开(公告)号：WO2017127664A1
公开(公告)日：2017-07-27
申请号：PCT/US2017/014311
申请日：2017-01-20
IPC分类号： C07K16/28 , C07K14/725 , A61K39/395 , A61P35/00
CPC分类号： C07K16/2803 , A61K47/6849 , A61K47/6889 , A61K47/6903 , A61K2039/505 , C07K14/705 , C07K14/7051 , C07K2317/24 , C07K2317/33 , C07K2317/73 , C07K2317/90 , C07K2317/92 , C07K2319/00 , C07K2319/03 , C12N9/12 , C12Y207/10001
摘要： ROR1 Antibody Compositions and Related Methods The disclosure provides antibodies, antibody drug conjugates, antibody-based fragments or antibody fragments (antigen-binding fragments), as well as antibody drug conjugates (ADCs) and chimeric antigen receptors (CARs), that specifically recognize human ROR1 and related compositions. Also provided in the disclosure are methods of using such antibodies in various diagnostic and therapeutic applications.
摘要翻译： ROR1抗体组合物和相关方法本公开提供抗体，抗体药物缀合物，基于抗体的片段或抗体片段（抗原结合片段）以及抗体药物缀合物（ADC）和嵌合抗原受体 （CAR），其特异性识别人ROR1和相关组合物。 本公开内容还提供了将这些抗体用于各种诊断和治疗应用的方法。
-
公开(公告)号：WO2019030240A1
公开(公告)日：2019-02-14
申请号：PCT/EP2018/071429
申请日：2018-08-07
IPC分类号： A61K19/00
摘要： An antibody or antigen-binding fragment thereof, or a chimeric antigen receptor (CAR), which competes for binding to a linear human CS1 epitope comprising an amino acid sequence according to SEQ ID NO. 1 with an antibody having a heavy chain/light chain amino acid sequence pair according to any one selected from the following pairs SEQ ID NO. 3 / SEQ ID NO. 4; SEQ ID NO. 5 / SEQ ID NO. 6; SEQ ID NO. 7 / SEQ ID NO. 8; SEQ ID NO. 9 / SEQ ID NO. 10; SEQ ID NO. 11/ SEQ ID NO. 12; SEQ ID NO. 13/ SEQ ID NO. 14, and/or SEQ ID NO. 15 / SEQ ID NO. 16.
-
公开(公告)号：WO2003034995A2
公开(公告)日：2003-05-01
申请号：PCT/US2002/033866
申请日：2002-10-22
IPC分类号： A61K
CPC分类号： B82Y5/00 , A61K47/64 , A61K47/67 , A61K47/6899
摘要： The present invention is directed to integrin targeting compounds comprising an integrin targeting component linked to a functio nal component such as a therapeutic agent or antibody. Structures of various integrin targeting compounds are provided. Additionally provided are methods of delivering a functional component to integrin associated with cells or tissue of an individual using the integrin targeting compounds. Also provided are methods of treating or preventing a disease or condition in an individual using the wherein said disease or condition involves an integrin using the integrin targeting compounds.
摘要翻译： 本发明涉及包含与功能成分如治疗剂或抗体连接的整联蛋白靶向组分的整联蛋白靶向化合物。 提供各种整合素靶向化合物的结构。 另外提供了使用整联蛋白靶向化合物将功能组分递送至与个体的细胞或组织相关的整联蛋白的方法。 还提供了使用其中所述疾病或病症涉及使用整联蛋白靶向化合物的整联蛋白治疗或预防个体的疾病或病症的方法。
-
公开(公告)号：WO2017127702A1
公开(公告)日：2017-07-27
申请号：PCT/US2017/014370
申请日：2017-01-20
发明人： RADER, Christoph , PENG, Haiyong , LI, Xiuling
IPC分类号： C07K16/28 , C07K14/725
CPC分类号： C07K16/2803 , A61K47/6809 , A61K47/6849 , A61K47/6889 , A61K2039/505 , C07K2317/24 , C07K2317/33 , C07K2317/73 , C07K2317/90 , C07K2317/92 , C07K2319/00
摘要： The disclosure provides antibodies, antibody fragments or antigen- binding fragments, as well as related antibody drug conjugates (ADCs) and chimeric antigen receptors (CARs), that specifically recognize human ROR2, Also provided in the disclosure are methods of using such antibodies in various diagnostic and therapeutic applications,
摘要翻译： 本公开提供了特异性识别人ROR2的抗体，抗体片段或抗原结合片段以及相关的抗体药物偶联物（ADC）和嵌合抗原受体（CAR）。本发明还提供了 是在各种诊断和治疗应用中使用这些抗体的方法，
-
公开(公告)号：WO2015048477A1
公开(公告)日：2015-04-02
申请号：PCT/US2014/057763
申请日：2014-09-26
申请人： H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. , UNIVERSITY OF SOUTH FLORIDA , THE SCRIPPS RESEARCH INSTITUTE OFFICE OF PATENT COUNSEL, TPC8 , MODULATION THERAPEUTICS
CPC分类号： C07K7/06 , A61K38/00 , C07K1/00 , C07K7/08 , C07K14/705 , C07K14/70596 , C07K2319/21 , C07K2319/30
摘要： The present invention concerns cyclic compounds, compositions comprising the cyclic compounds, linkers, a method of preparing a carrying agentxyclic compound adduct, a method for treating disorders such as proliferation disorders ( e.g. , malignancies), bone deficiency diseases, and autoimmune diseases, and a method for suppressing the growth of, or inducing apoptosis in, cells ( e.g. , malignant cells).
摘要翻译： 本发明涉及环状化合物，包含环状化合物的组合物，接头，制备载体化合物化合物加合物的方法，治疗诸如增生性疾病（例如恶性肿瘤），骨缺失疾病和自身免疫疾病等疾病的方法，以及 抑制细胞（例如恶性细胞）生长或诱导细胞凋亡的方法。
-
公开(公告)号：WO2021119012A1
公开(公告)日：2021-06-17
申请号：PCT/US2020/063809
申请日：2020-12-08
申请人： THE UNITED STATES OF AMERICA, as represented by the secretary, DEPARTMENT OF HEALTH AND HUMAN SERVICES , THE SCRIPPS RESEARCH INSTITUTE
发明人： WIESTNER, Adrian , RADER, Christoph , PENG, Haiyong , BASKAR, Sivasubramanian , GAGLIONE, Erika
摘要： Disclosed are anti-C3d antibodies or fragments thereof. Also disclosed are methods of killing cancer cells, methods of preparing anti-C3d antibodies, and pharmaceutical compositions.
-
7.发明申请
公开(公告)号：WO2021067290A1
公开(公告)日：2021-04-08
申请号：PCT/US2020/053303
申请日：2020-09-29
摘要： The present invention relates to compositions and methods for treating diseases, disorders or conditions associated with the expression of the glycosyl-phosphatidylinositol (GPI)-linked GDNF family protein α-receptor 4 (GFRα4).
-
公开(公告)号：WO2020076849A1
公开(公告)日：2020-04-16
申请号：PCT/US2019/055224
申请日：2019-10-08
发明人： RADER, Christoph , HWANG, Dobeen , NILCHAN, Napon
IPC分类号： A61K39/395 , A61K39/44 , C12N9/88 , C07K16/18
摘要： The present invention provides antibody compounds that contain a substitution of arginine for the reactive lysine residue (Lys99) in the hydrophobic cleft (38C2_Arg). The invention also provides antibody drug conjugate compounds (ADCs) that contain cargo moieties that are site-specifically conjugated to the engineered arginine residue in the 38C2_Arg variant antibody. Further provided in the invention are therapeutic applications of the compounds.
-
公开(公告)号：WO2021080846A1
公开(公告)日：2021-04-29
申请号：PCT/US2020/055768
申请日：2020-10-15
发明人： RADER, Christoph , HWANG, Dobeen
摘要： The present invention provides modified catalytic antibody 38C2 with arylation of the reactive lysine residue (Lys99). The Lys99 residue is arylated with a heteroaryl methyl sulfonyl compound such as methylsulfone phenyl oxadi azole (MS- PODA). The invention also provides antibody conjugated agents (e.g., antibody drug conjugates) that contain an agent moiety that is site-specifically conjugated to 38C2 via a methyl sulfonyl compound. Further provided in the invention are methods of making the antibody conjugated agents and therapeutic applications of the antibody conjugated agents.
-
公开(公告)号：WO2017049139A2
公开(公告)日：2017-03-23
申请号：PCT/US2016/052214
申请日：2016-09-16
CPC分类号： C07K16/32 , A61K47/6803 , A61K47/6849 , A61K47/6851 , A61K47/6855 , A61K2039/505 , C07K16/28 , C07K16/2896 , C07K2317/35 , C07K2317/55 , C07K2317/60 , C07K2317/73 , C07K2319/00
摘要： Dual variable domain (DVD) immunoconjugates and uses thereof are provided. Aspects of the subject immunoconjugates include a DVD immunoglobulin molecule having a first and a second variable domain, and a cargo moiety (e.g., a drug moiety) that is covalently conjugated to the second variable domain via a linker. Methods of making and using the subject immunoconjugates in the prevention and/or treatment of cancer and other diseases are also provided.
摘要翻译： 提供双重可变结构域（DVD）免疫偶联物及其用途。 受试者免疫偶联物的方面包括具有第一和第二可变结构域的DVD免疫球蛋白分子和经由连接体与第二可变结构域共价缀合的货物部分（例如药物部分）。 还提供了制备和使用受试者免疫缀合物以预防和/或治疗癌症和其它疾病的方法。
-
-
-
-
-
-
-
-
-
搜索结果
12 条记录 (耗时 0.015 秒)
